Leptin as a marker of multiple sclerosis activity in patients treated with interferon-beta

被引：81
|
作者：
Batocchi, AP
Rotondi, M
Caggiula, M
Frisullo, G
Odoardi, F
Nociti, V
Carella, C
Tonali, PA
Mirabella, M
机构：
[1] Catholic Univ, Neurol Inst, I-00168 Rome, Italy
[2] Univ Naples, F Magrassi Inst Endocrinol II, Dept Clin & Expt Med, I-80121 Naples, Italy
来源：
JOURNAL OF NEUROIMMUNOLOGY | 2003年 / 139卷 / 1-2期
关键词：
leptin; cytokines; multiple sclerosis; interferon beta;
D O I：
10.1016/S0165-5728(03)00154-1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
The role of leptin was investigated in relapsing-remitting multiple sclerosis (MS). Control and MS patients showed comparable baseline serum leptin levels. During the first year of IFNbeta-1a treatment, leptin significantly decreased since 2 months after starting therapy in 11 patients who had no relapses. A significant decrease in IL12/IL10 ratio was observed in this group of patients only after I year of treatment. An increase of leptin was observed before the first clinical exacerbation in 13 relapsing patients. Leptin may play a pathogenic role in MS and can be a useful marker of disease activity and response to therapy. (C) 2003 Elsevier Science B.V. All rights reserved.
引用
收藏
页码：150 / 154
页数：5
相关论文
共 50 条
  • [1] Depression in interferon-beta treated multiple sclerosis patients
    Guedes, R.
    Peixoto de Sousa, C.
    Curral, R.
    Silveira, C.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S466 - S467
  • [2] The measurement of antibodies binding to interferon-beta in Iranian multiple sclerosis patients treated with interferon-beta
    Jangouk, P
    Hooshmand, E
    Vaezeafshar, R
    Lotfi, J
    Amirzargar, A
    Nikbin, B
    JOURNAL OF NEUROLOGY, 2004, 251 : 64 - 64
  • [3] Arthritis and bursitis in multiple sclerosis patients treated with interferon-beta
    Strueby, L
    Nair, B
    Kirk, A
    Taylor-Gjevre, RM
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2005, 34 (06) : 485 - 488
  • [4] Antibodies to commercially available interferon-beta molecules in multiple sclerosis patients treated with natural interferon-beta
    Mayorga, C
    Luque, G
    Romero, F
    Guerrero, R
    Blanca, M
    Fernandez, O
    INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, 1999, 118 (2-4) : 368 - 371
  • [5] Interferon-beta neutralising antibodies in Canadian multiple sclerosis patients treated with different interferon-beta products
    Grossberg, S. E.
    Gehshan, A.
    Long, C.
    Chuppa, S. L.
    Nicholson, K.
    Grossberg, L. D.
    MULTIPLE SCLEROSIS, 2006, 12 : S207 - S208
  • [6] Subunits and isoforms of Interferon receptor in multiple sclerosis patients treated with Interferon-beta
    Serana, F.
    Capra, R.
    Ghidini, C.
    Guidolin, L.
    Imberti, L.
    EUROPEAN JOURNAL OF NEUROLOGY, 2009, 16 : 271 - 271
  • [7] Cellular immune responses in multiple sclerosis patients treated with interferon-beta
    Bustamante, M. F.
    Rio, J.
    Castro, Z.
    Sanchez, A.
    Montalban, X.
    Comabella, M.
    CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2013, 171 (03): : 243 - 246
  • [8] Inflammatory musculoskeletal manifestations in multiple sclerosis patients treated with interferon-beta
    Strueby, L
    Nair, B
    Kirk, A
    Taylor-Gjevre, R
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (07) : 1405 - 1405
  • [9] Interferon-beta specific T cells are associated with the development of neutralizing antibodies in interferon-beta treated multiple sclerosis patients
    Kalluri, Sudhakar Reddy
    Grummel, Verena
    Hracsko, Zsuzsanna
    Pongratz, Viola
    Pernpeintner, Verena
    Gasperi, Christiane
    Buck, Dorothea
    Hemmer, Bernhard
    JOURNAL OF AUTOIMMUNITY, 2018, 88 : 83 - 90
  • [10] Predictors of disability extremes in patients with multiple sclerosis treated with interferon-beta using the Swedish multiple sclerosis registry
    Fink, K.
    Glaser, A.
    Fogdell-Hahn, A.
    Hillert, J.
    JOURNAL OF NEUROLOGY, 2013, 260 : S262 - S262
12345